October 14, 2020 -- Rentschler Biopharma has signed a full contract development and manufacturing organization (CDMO) license agreement for Atum's leap-in transposase platform.
Under the agreement, Atum will provide Rentschler full access to its leap-in transposase platform. Atum's technology will advance Renstchler's cell line development services and capabilities and complement existing services offered through its CDMO strategic partner network. These services include the Chinese hamster ovary-glutamine synthetase-knockout (CHO-GS-KO) platform for difficult-to-express proteins, that together with the leap-in transposase platform will be well-suited for high-quality protein expression for designer protein therapeutics.
The leap-in transposase technology platform combines proprietary recoding algorithms, unique vector elements, and transposon-based mechanism for efficient insertion of genetically stable elements into the genome. The platform can be used to develop standard antibodies and multichain therapeutics proteins, such as bispecific monoclonal antibodies.
The companies will offer an additional service that will rapidly and robustly produce stable, high titer manufacturing cell lines to support organizations in moving biopharmaceuticals to market faster and with lower manufacturing risk.